Select Page

Do you have facial rosacea?

Rosacea is a skin disorder that affects 16 million Americans.  According to the National Rosacea Society (NRS), this number has jumped up by 2 million in the past ten years.  Since Rosacea occurs mainly on the cheeks and nose, it is common for those who suffer from this chronic skin condition to develop ocular rosacea (inflammation of the eyes).

Relationship between facial and ocular rosacea

In fact, many rosacea patients miss the connection between their dry eyes and skin disorder since eye discomfort is not usually associated with their facial manifestations from Rosacea.  

Since most people do not associate eye discomfort with a skin disorder and the symptoms can be severe, many rosacea patients may not recognize that they suffer from the ocular as well as the facial manifestations of the disorder.

What is Ocular Rosacea?

Ocular rosacea, or eye rosacea is a form of chronic dry eyes.  It causes burning, itching, and redness of the eyes.  In fact, ocular rosacea can often be the first sign that a person may later develop facial rosacea.  

Primarily affecting adults ages 30 to 50, this eye condition seems to develop in those who blush easily.  There is no cure for ocular rosacea, but with a good eye-care routine, the signs and symptoms can be controlled.

What are the Symptoms?

The symptoms of ocular rosacea are very much like that of chronic dry eyes.  It can occur in conjunction with, before, or even after facial rosacea symptoms occur.  The symptoms of ocular rosacea include:

  • Burning
  • Stinging
  • Dryness
  • Redness
  • Grittiness
  • Blurred Vision
  • Sensitivity to light
  • Visible small, dilated blood vessels in the whites of the eyes
  • Red, swollen eyelids
  • Tearing

The National Rosacea Society reports that up to 60 percent of rosacea patients surveyed reported watery or bloodshot eyes that were irritated, burning, or stinging.  In addition, styes and swollen eyelids are common. 

What are the Causes?

For patients who were diagnosed with ocular rosacea, eighty-five percent had meibomian glad dysfunction (clogged Meibomian oil glands located on the upper and lower eye lids).

The edge of the eyelid contains these glands that secrete a fatty substance to keep the surface of the eye from drying out.  When these glands become plugged, the result can be dry eyes, styes, or chalazions.  If left untreated, ocular rosacea go from a mild irritation to a severe condition that can damage the cornea and cause reduced visual acuity.

Research is continuing to uncover more information that will ultimately help doctors make a quicker diagnosis.  Studies have shown there are differences in the tears and saliva of rosacea patients and healthy patients on a molecular level.  

The presence of bacteria associated with Demodex mites in the eyelashes of ocular rosacea patients was thought to be a possible reaction to the mites or other microbes.

Other ocular rosacea causes include:

  • Heredity
  • Environmental factors
  • Bacterial involvement
  • Blocked meibomian glands in the eyelids
  • Eyelash mites- Demodex

Factors that may aggravate rosacea that are controllable by patients include limiting exposure to:

  • Hot or spicy foods
  • Alcohol
  • Extreme temperatures, wind, or sunlight
  • Stress, anger, or embarrassment
  • Hot baths or saunas
  • Certain medications that dilate blood vessels, such as cortisone creams
What are the Complications?

The surface of the eye, or cornea, may be affected by ocular rosacea, especially when there is a lack of tears from dry eyes.  When there are corneal complications, vision can be reduced.  

A second irritation of the cornea can be a result of blepharitis, an inflammation of the eyelids.  If left untreated, corneal complications can ultimately lead to vision loss.

What are Some Natural Treatment Options?

TheraLife has a complete line of natural products to maintain proper eye hygiene.  In addition, TheraLife natural dry eye relief addresses the primary cause of dry eyes:  underactive tear secretion.

Many ocular rosacea patients suffer from meibomian gland dysfunction, and TheraLife’s complete line of natural chronic dry eye relief products help the body heal from the inside out.  

Ocular Rosacea

Best ocular rosacea relief from TheraLife

With TheraLifes Eye Enhanced Starter Kit, patients suffering with dry eyes due to ocular rosacea will find relief with 4 bottles of TheraLife Eye Enhanced, 1 bottle of Omega-3 Fish Oil, 1 bottle of Eye Lid Cleanser, and 1 Hot Compress.  Stop suffering from dry eyes and start finding relief with TheraLife.

REFERENCES

1. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology:a review of recent findings. J Am Acad Dermatol. 2013;69:15–26. [
2. Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea-a review. Arq Bras Oftalmol. 2012;75(5):363–369. [PubMed[]
3. Michel JL, Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea. Ann Dermatol Venereol. 2003;130(1):20–24. [
4. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F, National Rosacea Society Expert Committee Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907–912. [
5. Eiseman AS. The ocular manifestations of atopic dermatitis and rosacea. Curr Allergy Asthma Rep. 2006;6(4):292–298. [
6. Oltz M, Check J. Rosacea and its ocular manifestations. Optometry. 2011;82(2):92–103. 
7. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;7421-27(3 Suppl):32–34. [
8. Suzuki T. Meibomitis-related keratoconjunctivitis: implications and clinicalsignificance of meibomian gland inflammation. Cornea. 2012;31(Suppl 1):S41–44. [
9. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283–2292. 
10. Vieira AC, Mannis MJ. Ocular rosacea: common and commonly missed. J Am Acad Dermatol. 2013;69(6 Suppl 1):S36–41
11. Määttä M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, Sorsa T. Tear fluid levels of MMP-8 are elevated in ocular rosacea-treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol. 2006;244(8):957–962. 
12. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur AcadDermatol Venereol. 2005;19(3):273–285. [
13. Iovieno A, Lambiase A, Micera A, Stampachiacchiere B, Sgrulletta R, Bonini S. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol. 2009;19(5):708–716. 
14. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130–145. 
15. Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011;9(11):904–907. [
16. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2(4):234–245. [
17. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–338. 
18. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474–510.
19. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol. 2011;152(1):33–39. 
20. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18(5):352–361
21. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(4 Suppl):3–6.
22. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–341.
23. Lazaridou E, Fotiadou C, Ziakas NG, Giannopoulou C, Apalla Z, Ioannides D. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatol Venereol. 2011;25(12):1428–1431. 
24. Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J EurAcad Dermatol Venereol. 2009;23(5):544–549. [
25. Vieira AC, An HJ, Ozcan S, Kim JH, Lebrilla CB, Mannis MJ. Glycomic analysis of tear and saliva in ocular rosacea patients: the search for a biomarker. Ocul Surf. 2012;10(3):184–192.
26. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22(3):230–233.
27. Yaylali V, Ozyurt C. Comparison of tear function tests and impression cytology with the ocular findings in acne rosacea. Eur J Ophthalmol. 2002;12(1):11–17. [
28. Baudouin C. A new approach for better comprehension of diseases of the ocularsurface. J Fr Ophtalmol. 2007;30(3):239–246. 
29. Wladis EJ, Carlson JA, Wang MS, Bhoiwala DP, Adam AP. Toll-like receptors and vascular markers in ocular rosacea. Ophthal Plast Reconstr Surg. 2013;29(4):290–293. 
30. Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19(4):492–496. [
31. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25(2):171–175. [
32. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26(6):651–659. 
33. Fallen RS, Gooderham M. Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012;17(10):1–4. [
34. Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129–140. 
35. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22(6):287–294. 

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Pin It on Pinterest